Glenmark Speclt Company Profile

What is the competitive landscape for GLENMARK SPECLT

GLENMARK SPECLT has twenty-nine approved drugs.

There are sixteen US patents protecting GLENMARK SPECLT drugs.

There are ninety-one patent family members on GLENMARK SPECLT drugs in thirty-four countries and one hundred and five supplementary protection certificates in sixteen countries.

Summary for Glenmark Speclt

International Patents:	91
US Patents:	16
Tradenames:	24
Ingredients:	23
NDAs:	29

Drugs and US Patents for Glenmark Speclt

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Speclt	APREPITANT	aprepitant	CAPSULE;ORAL	207777-002	Oct 12, 2017	AB	RX	No	No
Glenmark Speclt	CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE	betamethasone dipropionate; clotrimazole	CREAM;TOPICAL	202894-001	Oct 30, 2015		DISCN	No	No
Glenmark Speclt	RYALTRIS	mometasone furoate; olopatadine hydrochloride	SPRAY, METERED;NASAL	211746-001	Jan 13, 2022		RX	Yes	Yes	9,750,754		Y
Glenmark Speclt	FLUTICASONE PROPIONATE	fluticasone propionate	SPRAY, METERED;NASAL	218742-001	Mar 16, 2026		OTC	No	No
Glenmark Speclt	ACYCLOVIR	acyclovir	OINTMENT;TOPICAL	205510-001	Jul 31, 2017	AB	RX	No	No

International Patents for Glenmark Speclt Drugs

Country	Patent Number	Estimated Expiration
Cyprus	1124675
Canada	3088490
China	112773808
World Intellectual Property Organization (WIPO)	2015036902
Australia	2019224850

Supplementary Protection Certificates for Glenmark Speclt Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	SPC/GB04/011	United Kingdom		PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
0720599	CR 2014 00048	Denmark		PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Glenmark Generics
• Glenmark Pharms
• Glenmark Pharms Ltd
• Glenmark Speclt
• Glenwood

Glenmark Specialty (Glenmark Speclt): Competitive Landscape Analysis, Patent/Regulatory Position, and Generic/Biosimilar Risk

Last updated: June 17, 2026

Glenmark Specialty’s market position and near-term competitive exposure depend on the specific Glenmark “Speclt” portfolio assets tied to the relevant markets (US/Europe/India) and the relevant product-level patent estates. A patent and regulatory competitive landscape for “Glenmark Speclt” cannot be completed from the information provided because no specific drug(s), strength(s), dosage form(s), FDA NDA/BLA identifiers, Orange Book entries, or jurisdictional filings were supplied.

Key issue: which product(s)

• “Glenmark Speclt” can refer to different Glenmark specialty products across territories and time periods. Patent expiration timelines, Paragraph IV eligibility, exclusivity windows, and biosimilar/generic entry risks are product-specific and must be anchored to identifiable regulators listings and patent numbers.

Because no product identity was provided, the analysis below is omitted to avoid generating incomplete or inaccurate patent timelines and litigation/regulatory status.

Key Takeaways

• A complete competitive landscape for Glenmark Specialty requires product-level identification (active ingredient, dosage form, market, and regulator listing such as FDA NDA/BLA and Orange Book patents).
• Patent expiration, exclusivity, and generic entry risk are not computable at the portfolio label level.

FAQs

1. What portfolio-level factors determine generic and biosimilar entry risk for Glenmark Specialty?
2. How do Orange Book patent listings translate into Paragraph IV attack timing windows?
3. What litigation patterns most often affect US specialty product launch dates?
4. How do formulation and method-of-use patents change generic design-around strategies?
5. What commercial KPIs best predict which Glenmark Specialty products face near-term erosion?

References

(No sources cited because no product identifiers, regulator listings, or patent datasets were provided.)